Gallup Poll Released Tuesday July 7 (Sustained Coverage Through the Weekend): 1 in 9 US Adults (11%) Now Take a GLP-1 Medication for Weight Loss, Tripling From 3% in 2024 and Rising From 8% in 2025; US Adult Obesity Rate Fell From a Record 39.9% in 2022 to 36.4% in 2026, and Awareness of GLP-1 Drugs Climbed From 80% in 2024 to 91% in 2026; Diabetes Diagnosis Rate Held Steady After 15 Years of Slow Increase
Gallup released Tuesday July 7, 2026 poll results (survey conducted May-June 2026 with 5,000+ respondents across all 50 states and DC) showing 1 in 9 US adults (11%) now take a GLP-1 medication for weight loss. That share tripled from 3% in the 2024 survey and rose from 8% in 2025. The US adult obesity rate, which peaked at 39.9% in 2022, has drifted down to 36.4% in 2026, a statistically significant decline that inversely tracks the rise in GLP-1 use. Awareness of GLP-1 drugs for weight loss climbed from 80% in 2024 to 91% in 2026. Diagnosis of diabetes held steady after 15 years of slow increase in prior surveys. Follow-up coverage ran through Wednesday-Friday (Foreign Policy Journal, Forbes' Zachary Folk, Medscape, Fox 7 Austin, Bakery & Snacks) framing the results as the first large-population evidence that GLP-1 uptake is bending the US obesity curve. Payer analyst commentary tracked in parallel: employers continue steering workers toward cash-pay GLP-1 platforms as sticker prices stay high and adherence remains a concern (roughly two-thirds of non-T2D GLP-1 patients discontinue within one year).